Evidence map›Paper›PMID 36330660›Full record

ArticleNMR in biomedicine2023

Designing a quality assurance process for quality control of nuclear magnetic resonance metabolomics studies of human blood.

Isabella H Muti, Matteo Gonzalez Sanchez-Dahl, Anya B Zhong, JianXiang Weng, Mark V Füzesi, Pia Kivisäkk, Bradley T Hyman, Steven E Arnold, Adam S Feldman, Nathaniel D Mercaldo and 1 more

Open access · greenAbstract read
In one paragraph

Article in NMR in biomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Isabella H MutiMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Matteo Gonzalez Sanchez-DahlMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Anya B ZhongMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
JianXiang WengMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mark V FüzesiMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Pia KivisäkkMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Bradley T HymanMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Steven E ArnoldMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Adam S FeldmanMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Nathaniel D MercaldoMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Leo L ChengMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-5216-2306
Harvard University · US

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Christine S Ritchie · 2019 to 2026
$36.5M
Characterizing Prostate Cancer By ex vivo MRS SignaturesR01CA115746 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHENG, LEO L · 2006 to 2017
$6.4M
Metabolomic characterization of normal aging and Alzheimer's disease under anesthesia- surgery stimuliR01AG070257 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI JENKINS, BRUCE G, XIE, ZHONGCONG · 2021 to 2025
$3.9M
Novel metabolomic contrast probes for human lung cancer characterizationR01CA273010 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI FARRAR, CHRISTIAN T · 2022 to 2025
$3.3M
General Anesthesia and Alzheimer's Disease NeuropathogenesisRF1AG070761 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI XIE, ZHONGCONG · 2020 to 2020
$1.9M
Upgrade of Console for 600 MHz MR SpectrometerS10OD023406 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI CHENG, LEO L · 2017 to 2017
$600k
Identification of prostate cancer aggressiveness using hyperpolarized polyamine metabolic ratesR21CA243255 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI CHENG, LEO L · 2019 to 2020
$436k
NCI NIH HHS R01 CA115746NCI NIH HHS R01 CA273010NCI NIH HHS R21 CA243255NIA NIH HHS P30 AG062421NIA NIH HHS R01 AG070257NIA NIH HHS RF1 AG070761NIH HHS S10 OD023406
6 · The paper itself

Abstract

High-resolution magic angle spinning (HRMAS) nuclear magnetic resonance (NMR)-based metabolomics has demonstrated its utility in studies of biofluids for various diseases. HRMAS NMR spectroscopy is uniquely well suited for analyzing human blood samples because of the small quantity of samples and minimal preparation required. To develop this methodology into standardized clinical protocols, establishment of the method's quality assurance (QA) and evaluations of its quality control (QC) are critical. This study aims to assess the QA/QC measured from human blood specimens in the form of serum and plasma through within-subject and between-subject comparisons, as well as stability and consistency comparisons over several freezing-thawing cycles of sample storage conditions, and most importantly, the agreement of pooled control samples against individual samples.

Indexed as

Magnetic Resonance ImagingMetabolomicsHumansMagnetic Resonance Spectroscopymetabolomicsnuclear magnetic resonancequality assurancequality controlspectroscopy

Identifiers

PMID36330660
PMCPMC9992016
OpenAlexW4308181467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.